Qiagen חוב 2024

מה עושה Qiagen?

Qiagen NV is a biotechnology company based in Venlo, Netherlands. The company was founded in 1984 as a spin-off from the University of Düsseldorf and has since become a leading provider of molecular diagnostic products and systems. Qiagen operates in four business areas: Life Sciences, Molecular Diagnostics, Applied Testing, and Pharma. Life Sciences is the largest business area of the company and offers a wide range of products for DNA sequencing, gene expression, RNA isolation and analysis, as well as protein analysis. Molecular Diagnostics specializes in diagnostic tests for diseases such as cancer, infections, and genetic disorders. Applied Testing provides solutions for forensic analysis and food and environmental analysis, while Pharma offers products and services for drug discovery and development. In recent years, Qiagen has focused mainly on the development of molecular diagnostic tests for cancer and infection-related diseases such as HIV, hepatitis, and tuberculosis. These tests enable earlier detection of diseases and more targeted therapy, improving patient care and reducing healthcare costs. One example of a successful Qiagen product is the Cobas HPV Test, a molecular diagnostic test for the detection of human papillomaviruses (HPV) responsible for cervical cancer. The test is distributed by Roche Diagnostics and is one of the best-selling molecular diagnostic tests in the world. Qiagen also has a strong presence in academic research and is a major provider of tools and technologies for DNA sequencing and genome research. Customers include leading research institutes, universities, and pharmaceutical companies. In recent years, Qiagen has also expanded through acquisitions to expand its offering of products and technologies and enter new markets. For example, in 2018, the company acquired N-of-One, a provider of artificial intelligence in cancer diagnostics, and NeuMoDx Molecular, a provider of molecular diagnostic platforms for laboratories. In 2020, Qiagen also played a crucial role in the development of tests for the new coronavirus (SARS-CoV-2). The company, together with other leading diagnostic companies, developed molecular diagnostic tests for rapid and reliable diagnosis of COVID-19. Overall, Qiagen is an important player in the biotech industry, offering a wide range of products and services for molecular diagnostics, genome research, and pharmaceutical research. Qiagen has a strong competitive position due to its innovative products and technologies, strong presence in academic research, and strategic acquisitions to expand its product portfolio and market access. Qiagen ist eines der beliebtesten Unternehmen auf Eulerpool.com.